Melanoma Clinical Trials

In this phase I multiple dose, dose escalation study utilizing a classic 3+3 design. Sequential cohorts of patients will receive AEB1102 IV weekly at one of a series of increasing dose levels. Dose escalation will be dependent on the frequency of specific dose-limiting toxicities in the prior cohort of patients. ...

To compare overall survival (OS) of patients with resected Stage III and IV melanoma treated with physician/patient choice of either high dose interferon alfa-2b or ipilimumab versus MK-3475 (pembrolizumab)

The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in subjects with unresectable or metastatic melanoma.

The purpose of this study is to assess the safety, tolerability, and efficacy when combining INCB024360 and Nivolumab in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 (closed) and Phase 2 (open to enrollment)

This is an open label, non-randomized, multi-center study. The primary purpose of the study is to evaluate the safety, tolerability and efficacy of Epacadostat and Durvalumab when given in combination in patients with Selected Advanced Solid Tumors.

You are being asked to take part in this research study because you were diagnosed with a type of cancer called melanoma. Although your melanoma has been removed by surgery, you are at risk for having the melanoma come back (recur). People who are at risk for melanoma recurrence are ...

The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 (closed) and Phase 2 (open to enrollment)

This randomized phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy. Targeted therapy is a type of treatment that uses drugs or other substances ...

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01274338?term=E1609&rank=1

The purpose of the study is to develop new tests to predict the outcome of immunotherapy. There are up to 2 study visits. There may be the opportunity to participate in additional visits in the future. Each visit will last 30 to 50 minutes. There will be urine collection, survey, ...